Peter Lawson
Stock Analyst at Barclays
(1.44)
# 3,537
Out of 5,056 analysts
99
Total ratings
41.86%
Success rate
-11.87%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Peter Lawson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals | Maintains: Overweight | $19 → $22 | $17.09 | +28.73% | 5 | Nov 4, 2025 | |
| INCY Incyte | Maintains: Overweight | $90 → $101 | $103.89 | -2.78% | 1 | Oct 29, 2025 | |
| ONC BeOne Medicines AG | Initiates: Overweight | $385 | $363.92 | +5.79% | 1 | Sep 18, 2025 | |
| IDYA IDEAYA Biosciences | Initiates: Overweight | $40 | $33.71 | +18.66% | 1 | Sep 4, 2025 | |
| SDGR Schrödinger | Initiates: Overweight | $25 | $17.01 | +46.97% | 1 | Aug 14, 2025 | |
| REPL Replimune Group | Downgrades: Equal-Weight | $17 → $3 | $8.74 | -65.68% | 4 | Jul 23, 2025 | |
| EXEL Exelixis | Maintains: Equal-Weight | $29 → $40 | $42.65 | -6.21% | 6 | Jul 10, 2025 | |
| MGNX MacroGenics | Maintains: Overweight | $8 → $3 | $1.54 | +94.81% | 9 | May 14, 2025 | |
| FATE Fate Therapeutics | Maintains: Overweight | $10 → $2 | $1.02 | +96.08% | 4 | May 14, 2025 | |
| KPTI Karyopharm Therapeutics | Maintains: Overweight | $5 → $10 | $6.24 | +60.26% | 3 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $2.44 | +63.93% | 7 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $22 → $6 | $16.02 | -62.55% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $11 | $11.08 | -0.72% | 1 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $16 | $12.99 | +23.17% | 8 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $15 | $6.47 | +131.84% | 2 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $14 | $20.19 | -30.66% | 7 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $3 | $1.18 | +154.24% | 5 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $3 | $0.99 | +203.00% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $4 | $1.11 | +260.36% | 1 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $60 | $70.58 | -14.99% | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $17 | $6.51 | +161.14% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $66 | $38.06 | +73.41% | 2 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $31 | $12.68 | +144.48% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $13 | $8.00 | +62.50% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $1.68 | +197.62% | 4 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3.5 | $3.66 | -4.37% | 4 | Jul 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $355 → $365 | $121.97 | +199.25% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $46 | $45.49 | +1.12% | 2 | Oct 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $450 | $59.17 | +660.52% | 1 | Mar 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $17 → $45 | $2.62 | +1,617.56% | 2 | Jan 23, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $16 → $45 | $53.47 | -15.84% | 2 | Jan 23, 2018 |
Syndax Pharmaceuticals
Nov 4, 2025
Maintains: Overweight
Price Target: $19 → $22
Current: $17.09
Upside: +28.73%
Incyte
Oct 29, 2025
Maintains: Overweight
Price Target: $90 → $101
Current: $103.89
Upside: -2.78%
BeOne Medicines AG
Sep 18, 2025
Initiates: Overweight
Price Target: $385
Current: $363.92
Upside: +5.79%
IDEAYA Biosciences
Sep 4, 2025
Initiates: Overweight
Price Target: $40
Current: $33.71
Upside: +18.66%
Schrödinger
Aug 14, 2025
Initiates: Overweight
Price Target: $25
Current: $17.01
Upside: +46.97%
Replimune Group
Jul 23, 2025
Downgrades: Equal-Weight
Price Target: $17 → $3
Current: $8.74
Upside: -65.68%
Exelixis
Jul 10, 2025
Maintains: Equal-Weight
Price Target: $29 → $40
Current: $42.65
Upside: -6.21%
MacroGenics
May 14, 2025
Maintains: Overweight
Price Target: $8 → $3
Current: $1.54
Upside: +94.81%
Fate Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $10 → $2
Current: $1.02
Upside: +96.08%
Karyopharm Therapeutics
May 13, 2025
Maintains: Overweight
Price Target: $5 → $10
Current: $6.24
Upside: +60.26%
May 12, 2025
Maintains: Overweight
Price Target: $5 → $4
Current: $2.44
Upside: +63.93%
May 8, 2025
Maintains: Underweight
Price Target: $22 → $6
Current: $16.02
Upside: -62.55%
May 2, 2025
Maintains: Overweight
Price Target: $32 → $11
Current: $11.08
Upside: -0.72%
May 2, 2025
Maintains: Overweight
Price Target: $32 → $16
Current: $12.99
Upside: +23.17%
May 1, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $6.47
Upside: +131.84%
Apr 23, 2025
Maintains: Overweight
Price Target: $29 → $14
Current: $20.19
Upside: -30.66%
Apr 2, 2025
Maintains: Equal-Weight
Price Target: $11 → $3
Current: $1.18
Upside: +154.24%
Mar 7, 2025
Maintains: Overweight
Price Target: $14 → $3
Current: $0.99
Upside: +203.00%
Feb 27, 2025
Maintains: Overweight
Price Target: $9 → $4
Current: $1.11
Upside: +260.36%
Sep 27, 2024
Maintains: Overweight
Price Target: $54 → $60
Current: $70.58
Upside: -14.99%
Sep 10, 2024
Maintains: Overweight
Price Target: $14 → $17
Current: $6.51
Upside: +161.14%
Aug 9, 2024
Maintains: Overweight
Price Target: $92 → $66
Current: $38.06
Upside: +73.41%
Jul 15, 2024
Maintains: Overweight
Price Target: $20 → $31
Current: $12.68
Upside: +144.48%
May 24, 2024
Maintains: Overweight
Price Target: $18 → $13
Current: $8.00
Upside: +62.50%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $1.68
Upside: +197.62%
Jul 7, 2022
Maintains: Overweight
Price Target: $7 → $3.5
Current: $3.66
Upside: -4.37%
Aug 6, 2021
Maintains: Underweight
Price Target: $355 → $365
Current: $121.97
Upside: +199.25%
Oct 22, 2020
Upgrades: Overweight
Price Target: $46
Current: $45.49
Upside: +1.12%
Mar 4, 2020
Initiates: Overweight
Price Target: $450
Current: $59.17
Upside: +660.52%
Jan 23, 2018
Upgrades: Buy
Price Target: $17 → $45
Current: $2.62
Upside: +1,617.56%
Jan 23, 2018
Upgrades: Buy
Price Target: $16 → $45
Current: $53.47
Upside: -15.84%